Sona Nanotech Inc (SONA) AI Stock Analysis

55 Followers

Sona Nanotech Inc

(CNQX:SONA)

Select Model

Rating:40Underperform

Price Target:CAD 0.27▲(6.40% Upside)

Action:reiterated

Date:10/01/26

The score is severely depressed by the company's pre-revenue status, negative equity, and ongoing cash burn, which present a high risk of insolvency. While cost-cutting trends offer a faint positive signal, bearish technicals and a negative P/E ratio reinforce the weak outlook, leaving the stock near the lowest end of the scoring range.

Positive Factors

Proprietary Nanorod TechnologySona’s proprietary gold nanorod platform targets a clear performance advantage over traditional gold nanoparticles in diagnostic assays. If validated and adopted, improved sensitivity could support differentiated products, customer interest, and licensing or supply opportunities across life-science applications.

Negative Factors

No Revenue GenerationZero reported revenue means the business has not yet demonstrated commercial traction or validated customer demand through recurring sales. Without a revenue base, funding remains dependent on external capital or future partnerships, making execution and commercialization timing critical.

Sona Nanotech Inc (SONA) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 31.31M
Dividend Yield: ―
Average Volume (3M): 50.74K
Price to Earnings (P/E): -12.6
Beta (1Y): 0.86
Revenue Growth: ―
EPS Growth: 24.65%
Country: Canada
Employees: 8
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Sona Nanotech Inc Business Overview & Revenue Model

Company Description

Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lat...

How the Company Makes Money

Sona Nanotech’s primary monetization approach is expected to be the sale and supply of its proprietary gold nanorods (and potentially related reagents/materials) for use by diagnostics and life-sciences customers in assay development and production,...

Sona Nanotech Inc Financial Statement Overview

Summary

Pre-revenue company with persistent net losses and negative equity, indicating severe financial distress. Positively, operating and cash flow losses are narrowing, showing improved cost control, but the balance sheet deficit and zero revenue keep the score near the floor.

Income Statement

1Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Jan 2026	Jan 2025	Jan 2024	Jan 2023	Jan 2022
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-720.00K	-720.00K	-733.98K	-457.00K	-60.32K	-65.59K
EBITDA	-1.90M	-2.72M	-2.00M	-2.02M	-2.34M	-10.38M
Net Income	-2.44M	-3.25M	-2.70M	-2.50M	-2.36M	-10.77M
Balance Sheet
Total Assets	542.77K	1.33M	3.75M	2.75M	520.77K	1.52M
Cash, Cash Equivalents and Short-Term Investments	17.21K	125.95K	1.86M	115.38K	164.42K	1.20M
Total Debt	340.16K	307.74K	394.67K	527.68K	608.47K	1.34M
Total Liabilities	1.81M	1.37M	1.24M	1.59M	1.03M	2.75M
Stockholders Equity	-1.26M	-38.78K	2.51M	1.16M	-507.86K	-1.22M
Cash Flow
Free Cash Flow	-894.27K	-1.96M	-1.96M	-1.26M	-1.81M	-3.81M
Operating Cash Flow	-894.26K	-1.96M	-1.96M	-1.26M	-1.81M	-3.81M
Investing Cash Flow	0	0	0	14.64K	0	0
Financing Cash Flow	521.44K	228.43K	3.70M	1.20M	778	4.89M

Sona Nanotech Inc Technical Analysis

Technical Analysis SentimentNegative

Last Price0.25

Price Trends

50DMA0.32Negative

100DMA0.32Negative

200DMA0.33Negative

Market Momentum

MACD-0.01Negative

RSI35.04Neutral

STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Negative. The current price of 0.25 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.32, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 35.04 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SONA.

Sona Nanotech Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:SONA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:EBM	56Neutral	CAD 117.11M	-564.52	13.66%	―	36.59%	43.33%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:MIR	47Neutral	CAD 31.58M	-7.95	12.68%	―	45.72%	35.82%
TSE:SONA	40Underperform	CAD 30.70M	-12.62	448.05%	―	―	24.65%
TSE:BUX	37Underperform	CAD 44.72M	-31.11	-250.77%	―	-82.05%	23.73%

* Healthcare Sector Average

Performance Comparison

TSE:SONA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:SONA	Sona Nanotech, Inc	0.25	-0.26	-50.98%
TSE:BUX	BioMark Diagnostics	0.42	0.07	20.00%
TSE:EBM	Eastwood Bio-Medical Canada	1.75	1.00	133.33%
TSE:SZLS.H	Stagezero Life Sciences	0.04	0.00	0.00%
TSE:MIR	Medmira Inc	0.04	-0.04	-50.00%
TSE:ZYUS	Zyus Life Sciences Corporation	0.40	-0.29	-42.03%

Sona Nanotech Inc Corporate Events

Business Operations and StrategyExecutive/Board Changes

Sona Nanotech Elevates CTO and Grants Options to Fund Cancer Therapy Push

Positive

Oct 13, 2026

Sona Nanotech Inc. has appointed company co-founder and core technology co-inventor Dr. Kulbir Singh as Chief Technology Officer, formalizing his leadership role in advancing the firm’s Targeted Hyperthermia delivery system toward commercialization....

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026

Sona Nanotech Inc AI Stock Analysis